Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study
- PMID: 19383883
- PMCID: PMC2814542
- DOI: 10.1158/1055-9965.EPI-08-1214
Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study
Abstract
Hormone receptor expression in tumors may offer etiologic information for ovarian cancer, particularly in light of known associations with hormonal and reproductive risk factors. Tissue microarrays constructed from 157 paraffin-embedded blocks of epithelial ovarian tumors collected from participants in the Nurses' Health Study were stained for estrogen receptor-alpha (ERalpha) and progesterone receptor (PR). We examined receptor expression by invasion, grade, and histologic subtype. Multivariate unconditional logistic regression was used to evaluate whether hormonal, reproductive, and anthropometric risk factors were differentially associated with the risk of developing receptor-positive or receptor-negative ovarian tumors compared with controls. PR-expressing tumors were less likely to be invasive (P = 0.05) and more likely to be of a lower grade (P < 0.001) and stage (P = 0.007) compared with PR- tumors. ERalpha status was not associated with any pathologic features of the tumor (P > 0.34). Increasing age, being postmenopausal, and postmenopausal hormone use were associated with an increased risk of developing ERalpha+, but not ERalpha- (P(heterogeneity) = 0.001, 0.06, and 0.06, respectively) and PR-, but not PR+, tumors (P(heterogeneity) = 0.08, 0.003, and 0.40, respectively), whereas height was only associated with the risk of developing PR- disease (P(heterogeneity) = 0.08). There were no clear risk differentials with OC use, parity, body mass index, or physical activity. Reproductive and hormonal risk factors are associated with subgroups of ovarian cancer defined by histologic subtype or ERalpha and PR status. These finding support specific models of hormone mediated triggers of ovarian cancer.
Similar articles
-
The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status.Gynecol Oncol. 2016 Dec;143(3):628-635. doi: 10.1016/j.ygyno.2016.09.024. Epub 2016 Oct 5. Gynecol Oncol. 2016. PMID: 27720231 Free PMC article.
-
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9. Lancet Oncol. 2013. PMID: 23845225 Free PMC article.
-
Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.Oncol Rep. 2007 Nov;18(5):1051-9. Oncol Rep. 2007. PMID: 17914554
-
Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors.Int J Gynecol Pathol. 2007 Oct;26(4):375-82. doi: 10.1097/pgp.0b013e31805c0d99. Int J Gynecol Pathol. 2007. PMID: 17885486
-
Ovarian Cancer-Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors' Molecular Backgrounds.Int J Mol Sci. 2025 May 12;26(10):4611. doi: 10.3390/ijms26104611. Int J Mol Sci. 2025. PMID: 40429755 Free PMC article. Review.
Cited by
-
Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review).Oncol Lett. 2013 Nov;6(5):1163-1173. doi: 10.3892/ol.2013.1550. Epub 2013 Aug 28. Oncol Lett. 2013. PMID: 24179489 Free PMC article.
-
Predictors of residual disease after debulking surgery in advanced stage ovarian cancer.Front Oncol. 2023 Jan 24;13:1090092. doi: 10.3389/fonc.2023.1090092. eCollection 2023. Front Oncol. 2023. PMID: 36761962 Free PMC article.
-
A retrospective analysis of clinicopathological and prognostic characteristics of ovarian tumors in the State of Espírito Santo, Brazil.J Ovarian Res. 2011 Aug 9;4:14. doi: 10.1186/1757-2215-4-14. J Ovarian Res. 2011. PMID: 21827671 Free PMC article.
-
Checkpoint kinase 1 inhibitors as targeted molecular agents for clear cell carcinoma of the ovary.Oncol Lett. 2015 Aug;10(2):571-576. doi: 10.3892/ol.2015.3268. Epub 2015 May 26. Oncol Lett. 2015. PMID: 26622535 Free PMC article.
-
Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries.Br J Cancer. 2017 Apr 11;116(8):1088-1091. doi: 10.1038/bjc.2017.73. Epub 2017 Mar 23. Br J Cancer. 2017. PMID: 28334730 Free PMC article.
References
-
- Beral V, Banks E, Reeves G. Effects of estrogen-only treatment in postmenopausal women. Jama. 2004 Aug 11;292:684. author reply 5–6. - PubMed
-
- Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. Jama. 2001 Mar 21;285:1460–1465. - PubMed
-
- Lacey JV, Jr, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. Jama. 2002 Jul 17;288:334–341. - PubMed
-
- Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology. 2004 Jan;15:100–104. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials